Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (61-70 of 198) with videos related to

Pageof 20
Sort By:
The Oncologist|April 8, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directionsAlessandro Morabito, Maria Carmela Piccirillo, Fabiano Falasconi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2012
Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinibAlessandro Morabito, Claudia Sandomenico, Raffaele Costanzo, et al.
Cells|June 25, 2026
MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer CellsBrigitta Ignoto, Ilaria Assunta Parisi, Cristin Roma, et al.
Pharmacogenomics and Personalized Medicine|December 11, 2012
Optimizing response to gefitinib in the treatment of non-small-cell lung cancerPietro Carotenuto, Cristin Roma, Anna Maria Rachiglio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2016
ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS StudyMartin Reck, Koichi Hagiwara, Baohui Han, et al.
Breast Cancer Research and Treatment|March 4, 2003
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II studyAlessandro Morabito, Gianfranco Filippelli, Sergio Palmeri, et al.
Expert Review of Anticancer Therapy|October 19, 2013
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectivesRaffaele Costanzo, Agnese Montanino, Massimo Di Maio, et al.
Critical Reviews in Oncology/Hematology|April 29, 2014
Treatment of small cell lung cancerAlessandro Morabito, Guido Carillio, Gennaro Daniele, et al.
Journal of Translational Medicine|October 22, 2014
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014Paolo A Ascierto, Raffaele Addeo, Giacomo Cartenì, et al.
Translational Lung Cancer Research|September 15, 2017
Clinical utility of circulating tumor cells in patients with non-small-cell lung cancerMarianna Gallo, Antonella De Luca, Monica Rosaria Maiello, et al.
Pageof 20

Showing results (61-70 of 198) with videos related to

Sort By:
Pageof 20
The Oncologist|April 8, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directionsAlessandro Morabito, Maria Carmela Piccirillo, Fabiano Falasconi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2012
Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinibAlessandro Morabito, Claudia Sandomenico, Raffaele Costanzo, et al.
Cells|June 25, 2026
MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer CellsBrigitta Ignoto, Ilaria Assunta Parisi, Cristin Roma, et al.
Pharmacogenomics and Personalized Medicine|December 11, 2012
Optimizing response to gefitinib in the treatment of non-small-cell lung cancerPietro Carotenuto, Cristin Roma, Anna Maria Rachiglio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2016
ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS StudyMartin Reck, Koichi Hagiwara, Baohui Han, et al.
Breast Cancer Research and Treatment|March 4, 2003
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II studyAlessandro Morabito, Gianfranco Filippelli, Sergio Palmeri, et al.
Expert Review of Anticancer Therapy|October 19, 2013
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectivesRaffaele Costanzo, Agnese Montanino, Massimo Di Maio, et al.
Critical Reviews in Oncology/Hematology|April 29, 2014
Treatment of small cell lung cancerAlessandro Morabito, Guido Carillio, Gennaro Daniele, et al.
Journal of Translational Medicine|October 22, 2014
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014Paolo A Ascierto, Raffaele Addeo, Giacomo Cartenì, et al.
Translational Lung Cancer Research|September 15, 2017
Clinical utility of circulating tumor cells in patients with non-small-cell lung cancerMarianna Gallo, Antonella De Luca, Monica Rosaria Maiello, et al.
Pageof 20